進行性または転移性非小細胞肺がんの参加者におけるAZD2936の安全性と有効性を評価するための研究 (ARTEMIDE-01)
進行性または転移性非小細胞肺癌の参加者におけるAZD2936抗TIGIT /抗PD-1抗体の安全性、薬物動態、薬力学、および有効性を評価するための第I / II相、非盲検、用量漸増および用量拡大試験
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- Research Site
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Research Site
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Research Site
-
-
-
-
-
Groningen、オランダ、9713 GZ
- Research Site
-
Leiden、オランダ、2333 ZA
- Research Site
-
Utrecht、オランダ、3584 CX
- Research Site
-
-
-
-
-
Melbourne、オーストラリア、3000
- Research Site
-
-
-
-
-
Tbilisi、グルジア、0112
- Research Site
-
-
-
-
-
Barcelona、スペイン、08035
- Research Site
-
Madrid、スペイン、28041
- Research Site
-
Madrid、スペイン、28027
- Research Site
-
-
-
-
-
Bangkok、タイ、10700
- Research Site
-
Chanthaburi、タイ、22000
- Research Site
-
Muang、タイ、50200
- Research Site
-
-
-
-
-
Copenhagen、デンマーク、2100
- Research Site
-
-
-
-
-
Dijon、フランス、21079
- Research Site
-
Toulouse、フランス、31059
- Research Site
-
-
-
-
-
Florianópolis、ブラジル、88034-000
- Research Site
-
Natal、ブラジル、59075-740
- Research Site
-
Porto Alegre、ブラジル、90035903
- Research Site
-
Rio de Janeiro、ブラジル、20231-050
- Research Site
-
São Paulo、ブラジル、01246-000
- Research Site
-
-
-
-
-
Anderlecht、ベルギー、1070
- Research Site
-
Leuven、ベルギー、3000
- Research Site
-
-
-
-
-
Kuala Lumpur、マレーシア、59100
- Research Site
-
Kuching、マレーシア、93586
- Research Site
-
-
-
-
-
Chisinau、モルドバ、MD-2025
- Research Site
-
-
-
-
-
Chengdu、中国、610041
- Research Site
-
Chongqing、中国、400030
- Research Site
-
-
-
-
-
Taichung、台湾、40705
- Research Site
-
Taichung、台湾、40201
- Research Site
-
Tainan、台湾、70403
- Research Site
-
Taipei、台湾、110
- Research Site
-
-
-
-
-
Kashiwa、日本、227-8577
- Research Site
-
Niigata、日本、951-8566
- Research Site
-
Sendai、日本、981-0914
- Research Site
-
Tokyo、日本、104-0045
- Research Site
-
-
-
-
-
Seoul、韓国、03722
- Research Site
-
Seoul、韓国、05505
- Research Site
-
Seoul、韓国、03082
- Research Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Written informed consent
- Aged 18 or above
- Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
- Documented PD-L1 expression by PD-L1 IHC per local report.
- Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
- Part C and Part D: No prior I/O treatment for metastatic NSCLC.
- Part E: No prior treatment for metastatic NSCLC.
- ECOG performance status of 0 or 1 at enrolment.
- Life expectancy of ≥ 12 weeks at enrolment.
- Have at least 1 measurable lesion per RECIST v1.1.
- Adequate bone marrow, liver and kidney function
Exclusion Criteria:
- Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
- Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
- Previous treatment with an anti-TIGIT therapy
- Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
- Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
- Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).
Treatment with one previous systemic chemotherapy will be allowed.
- Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.
- Symptomatic central nervous system (CNS) metastasis.
- Thromboembolic event within 3 months prior to enrolment.
- Other invasive malignancy within 2 years prior to screening.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)
Rilvegostomig Intravenous (IV) monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
他の名前:
|
|
実験的:Dose Expansion Part B: CPI experienced NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
他の名前:
|
|
実験的:Dose Expansion Part C: CPI Naive NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
他の名前:
|
|
実験的:Dose Expansion Part D: CPI Naive NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
他の名前:
|
|
実験的:Dose Expansion Part E: treatment Naive Squamous NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
時間枠:Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
|
A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness. |
Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
|
|
Rate of rilvegostomig discontinuation due to toxicity
時間枠:Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
|
Percentage of participants with AEs leading to discontinuation of rilvegostomig |
Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
|
|
Objective Response Rate (ORR)
時間枠:Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)
|
Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 |
Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ORR
時間枠:Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
Percentage of participants with a confirmed CR or PR according to RECIST v1.1 |
Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
|
Disease control rate (DCR)
時間枠:Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
Percentage of participants who have a best objective response of confirmed CR or PR or who have SD lasting for at least a certain time of period after start of treatment |
Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
|
Duration of response (DoR)
時間枠:Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
The time from first response according to RECIST v1.1 until progression or death in the absence of disease progression |
Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
|
Durable response rate (DRR)
時間枠:Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
The percentage of participants according to RECIST v1.1 with a confirmed CR or PR lasting 6 months or more |
Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
|
Progression-free survival (PFS)
時間枠:Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
The time from first dose of study intervention until the date of objective disease progression or death in the absence of disease progression |
Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
|
Measure the receptor occupancy (RO) of TIGIT and PD-1 on peripheral blood
時間枠:Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.
|
Evaluation of the target engagement of rilvegostomig in peripheral blood |
Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.
|
|
PK of rilvegostomig: Maximum plasma concentration of the study drug (Cmax)
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Maximum observed plasma concentration of rilvegostomig |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
PK of rilvegostomig: Area under the concentration-time curve (AUC)
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Area under the plasma concentration-time curve |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
PK of rilvegostomig: Clearance
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
A pharmacokinetic measurement of the volume of plasma from which the study intervention is completely removed per unit time. |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
PK of rilvegostomig: Terminal elimination half-life (t 1/2)
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Terminal elimination half life |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
Incidence of anti-drug antibodies (ADA) against rilvegostomig in serum
時間枠:From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Immunogenicity of rilvegostomig |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- D7020C00001
- 2021-000857-23 (EudraCT番号)
- 2023-508262-15-00 (レジストリ識別子:EU CT Number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共有時間枠
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有アクセス基準
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。